Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cascadian Therapeutics, Inc.

http://www.cascadianrx.com/

Latest From Cascadian Therapeutics, Inc.

SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.

Commercial Financing

Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs

Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.

Deals Cancer

Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO

Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

Deals Business Strategies

Ocugen Eyes Broad Retinitis Pigmentosa Indication With One Gene Therapy

Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.

StartUps and SMEs Gene Therapy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alpine Biosciences
    • Biomira
    • Oncothyreon, Inc.
    • Seattle Genetics, Inc.s
UsernamePublicRestriction

Register